Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 13/20 | 0.35 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935850 | 0.80 | DPP4 (0.48) | P2RX7DPP4DPP8DPP7 | |
| SCHEMBL5935844 | 0.76 | DPP4 (0.49) | P2RX7DPP4CYP8B1DPP8DPP9 | |
| SCHEMBL5653362 | 0.76 | DPP4 (0.49) | P2RX7DPP4CYP8B1DPP8DPP9 | |
| SCHEMBL29649992 | 0.72 | DPP4 (0.42) | P2RX7DPP4CYP8B1DPP8DPP7 | |
| SCHEMBL29650119 | 0.71 | CYP8B1 (0.49) | P2RX7DPP4CYP8B1DPP8DPP9 | |
| SCHEMBL16790034 | 0.71 | DPP4 (0.39) | DPP4CYP8B1DPP8DPP9GPR119 | |
| SCHEMBL16789995 | 0.71 | DPP4 (0.41) | DPP4DPP8DPP9CETP | |
| SCHEMBL16790052 | 0.70 | DPP4 (0.32) | DPP4DPP8MAPTDPP9DPP7 | |
| SCHEMBL16790038 | 0.70 | DPP4 (0.38) | DPP4DPP8DPP9GPR119 | |
| SCHEMBL16790044 | 0.70 | DPP4 (0.42) | P2RX7DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307164-B2 | β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107390-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | P2RX7 1712/4885DPP4 1/4885CYP8B1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.